Royalty Pharma plc (RPRX) has a consensus analyst rating of Buy, based on 11 analysts covering the stock. Of those, 10 recommend buying, 1 recommend holding, and 0 recommend selling.
The analyst consensus price target for RPRX is $51.25, representing a +5.0% upside from the current price of $48.82. Price targets range from a low of $45.00 to a high of $61.00.
